Krepart GV - Search Results

1

A predictive index of cure versus no cure in advanced ovarian carcinoma patients--replacement of second-look laparotomy as a diagnostic test.

Carmichael JA, Shelley WE, Brown LB, Fraser RC, Kirk ME, Krepart GV, Levitt M, Roy M, Willan AR, Wilson KS. Carmichael JA, et al. Among authors: krepart gv. Gynecol Oncol. 1987 Jul;27(3):269-81. doi: 10.1016/0090-8258(87)90246-0. Gynecol Oncol. 1987. PMID: 3623227

2

Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging.

Monga M, Carmichael JA, Shelley WE, Kirk ME, Krepart GV, Jeffrey JF, Pater JL. Monga M, et al. Among authors: krepart gv. Gynecol Oncol. 1991 Dec;43(3):195-7. doi: 10.1016/0090-8258(91)90018-z. Gynecol Oncol. 1991. PMID: 1752486 Clinical Trial.

3

Adriamycin and cisplatin in the treatment of stage III and IV epithelial ovarian carcinoma.

Shelley WE, Carmichael JC, Brown LB, Fraser RC, Kirk ME, Krepart GV, Levitt M, Roy M, Willan AR, Wilson KS. Shelley WE, et al. Among authors: krepart gv. Gynecol Oncol. 1988 Feb;29(2):208-21. doi: 10.1016/0090-8258(88)90215-6. Gynecol Oncol. 1988. PMID: 3338672

4

High-dose-intensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with stage III and IV epithelial ovarian carcinoma.

O'Connell G, Shelley W, Carmichael J, Fraser R, Kirk ME, Krepart G, Levin L, Swenerton K. O'Connell G, et al. Cancer Treat Rep. 1987 May;71(5):455-8. Cancer Treat Rep. 1987. PMID: 3567969

5

Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.

Pater JL, Carmichael JA, Krepart GV, Fraser RC, Roy M, Kirk ME, Levitt M, Brown LB, Wilson KS, Shelley WE, et al. Pater JL, et al. Among authors: krepart gv. Cancer Treat Rep. 1987 Mar;71(3):277-81. Cancer Treat Rep. 1987. PMID: 3102056 Clinical Trial.

6

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, et al. Swenerton K, et al. J Clin Oncol. 1992 May;10(5):718-26. doi: 10.1200/JCO.1992.10.5.718. J Clin Oncol. 1992. PMID: 1569444 Clinical Trial.

7

Factor analysis of false-negative second-look laparotomy.

Ghatage P, Krepart GV, Lotocki R. Ghatage P, et al. Among authors: krepart gv. Gynecol Oncol. 1990 Feb;36(2):172-5. doi: 10.1016/0090-8258(90)90167-j. Gynecol Oncol. 1990. PMID: 2298405

8

Clinically apparent early stage invasive epithelial ovarian carcinoma: should all be treated similarly?

Le T, Krepart GV, Lotocki RJ, Heywood MS. Le T, et al. Among authors: krepart gv. Gynecol Oncol. 1999 Aug;74(2):252-4. doi: 10.1006/gyno.1999.5440. Gynecol Oncol. 1999. PMID: 10419740

9

The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.

Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS. Le T, et al. Among authors: krepart gv. Gynecol Oncol. 2002 May;85(2):351-5. doi: 10.1006/gyno.2002.6636. Gynecol Oncol. 2002. PMID: 11972399

10

Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20-year experience.

Le T, Krepart GV, Lotocki RJ, Heywood MS. Le T, et al. Among authors: krepart gv. Gynecol Oncol. 1997 May;65(2):237-40. doi: 10.1006/gyno.1997.4625. Gynecol Oncol. 1997. PMID: 9159331

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters